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PP-087 Investigation of HBV infection rate and virus
genotypes of Yao population in Guangdong
Ruyuan
C.-S. Lin1 *, D.-C. Li2, C. Ma2. 1The Third Afﬁliated Hospital
of Sun Yat-sen University, 2The Second People’s Hospital of
Yue-Bei, China
Objective: To explore the infection rate of HBV of Yao
population in Ruyuan and the correction between Hepatitis B
virus genotypes and clinical disease spectra.
Methods: ELISA was used to detect hepatitis B virus
markers of 665 Yao population and 589 Han population.
And microboard nucleate molecular hybridization ELISA was
used to detect the genotype of 97 cases of different clinical
types of HBV infections.
Results: HBsAg positive rate of Yao population (20.3%)
was higher than Han population (13.4%), and signiﬁcance
difference was found in males (25.81% vs 13.22%, P< 0.05).
Among the 97 HBV patients of Yao population, genotype B
took up the largest proportion (52.58%, 51/97), followed
by genotype C (36.08%, 35/97), and then 7 cases of mixed
genotype (4 cases of B/C, 3 cases of C/D). No genotype E
or F was detected. Genotype B was higher than genotype C
(52.94% vs 25.71%, p < 0.05) in asymptomatic carriers, while
genotype C was higher than genotype B (62.85% vs 27.45%,
p < 0.05) in mild or moderate chronic hepatitis B.
Conclusion: HBsAg positive rate of males in Ruyuan of
Yao population was higher than that of Han population.
Genotype B was the main type in this area, followed by
genotype C.
PP-088 Incidence of genotypic resistance to lamivudine
long-term therapy in chronic hepatitis B
genotype D
W. Osman1, N. Allam1 *, M. Hassouna1, A. Abdelmoneim1,
A. Roshdy1, I. Waked1. 1National Liver Institute, Egypt
Background: Lamivudine improves patients’ outcome but
is reported to be associated with increasing rates of viral
resistance. The long-term beneﬁt of lamivudine therapy and
resistance rate in HBeAg negative genotype D patients is not
fully known. The aim of the present study was to assess the
incidence of genotypic resistance to lamivudine therapy in
patients with chronic hepatitis B due to genotype D.
Methods: This study included 85 patients with chronic
hepatitis B due to genotype D, who received lamivudine
100mg daily for at least 12 months (10 females, age
32±8 years). 73 (85) % were HBeAg negative. Mean follow
up period was 25±10 months (33 patients for 12 24m, 27
for 24 36m, 20 for 36 48 and 5 for 48 60m).
Results: HBV-DNA decreased to <2000 IU/ml in 25 patients
(21%), and HBV-DNA became undetectable in 42 (35.7%)
during the ﬁrst year of treatment. The rate of relapse
with either HBV-DNA reverting to positive or increasing to
>2000 IU/ml after initial response was 16% during the ﬁrst
year, 19% during the second year, 3.5% during the third,
1% during the fourth year of follow up. Breakthrough was
observed in 66% of the HBeAg positive group and only 35%
of the HBeAg negative group. INNO-LiPA was performed for
20 patients. Wild type was found in 14 patients; mixed type
in 4 and mutant in two patients. Hence mutations were
detected in 30% of the tested lamivudine-treated cases.
YMDD was detected in 15%. Mean viral load was 283746
IU/ml compared to 5,673000 IU/ml in the patients with the
mutants.
Conclusion: Longterm lamivudine therapy is associated with
a high response rate with a rather low relapse rate in HBeAg
negative patients with genotype D. The incidence of YMDD
mutation is low.
PP-089 Improving blood safety by setting the ambiguous
region of screening HBsAg ELISA in Chinese
blood donations
Y.Y. Lin1 *, X.J. Ling1. 1Nanjing Red Cross Blood Center,
China
Objective: To evaluate to set ambiguous region of screening
HBsAg ELISA results whether improving blood safety by
HBsAg conﬁrmatory assay and super-sensitivity screening
kits.
Method: The samples, which HBsAg screening results were
in ambiguous region, were retested by HBsAg conﬁrmatory
assay using hepatitis B immunoglobulin and super-sensitivity
screening kits.
Results: The 21 samples were positive tested by HBsAg
super-sensitivity screening kits, in which 15 samples were
positive conﬁrmed by HBsAg conﬁrmatory assay and other
6 samples were false positive. The average S/CO value of
negative samples, which retested by HBsAg super-sensitivity
screening kits, was not signiﬁcance rise compared with other
two routine HBsAg screening kits in our laboratory.
Conclusion: Setting ambiguous region of screening HBsAg
ELISA in Chinese blood donations improved blood safety and
prevented HBsAg screening failure.
PP-090 Hepatitis B, C and D viruses in Tajikistan
D. Abdusamad1 *. 1The Institute of Gastroenterology of
the Ministry of Health of the Republic of Tajikistan,
Tajikistan
Aim: To study was to investigate the genotypic prevalence
and clinical signiﬁcance of HCV, HBV, and/or HDV among
chronic hepatitis patients with and without liver cirrhosis
and/or HCC in Tajikistan.
Methods: Sera were obtained from 124 consecutive cases of
chronic liver diseases. Patients in this study were classiﬁed
into two clinical groups: (i) chronic hepatitis and (ii) liver
cirrhosis.
Results: Genotypes of HBV, HCV, and HDV were determined
by genetic sequencing. The overall prevalence of anti-HCV,
HCV core antigen (HCVcAg) and HBsAg was 46% (57/124)
and 41.1% (51/124), respectively. Co-infection of HCV/HBV,
HBV/HDV, and HCV/HBV/HDV was found in 4.8% (6/124),
11.2% (12/124), and 0.8% (1/124) of cases, respectively.
HDV genotype 1 was found in 19.6% (10/51) of HBsAg-
positive patients. The HBV/HDV co-infection was relatively
high in group 2 compared with group 1 (15% vs. 7.1%).
HCV/1b was detected in 84.6% (44/52) of HCV RNA-positive
patients, followed by 3a (7.6%), 2a (5.7%), and 2c (1.9%).
HBV/D was detected in 94.1% (48/51) of HBsAg-positive
patients, followed by HBV/A [5.8% (3/51)]. T1762/A1764
double mutation was associated with liver cirrhosis in HBV-
infected patients (P= 0.0004).
Conclusion: Among HBV-infected patients, the T1762/A1764
mutation was associated with liver cirrhosis.
PP-091 Protective effect of caffeic acid phenethyl ester
on liver injury model in rats
S.S. Dang1 *, S. Zhai1, X.F. Wang1, Y.P. Li1, W.J. Wang1,
X. Zhang1, Y. Wang1. 1Department of Infectious Diseases,
the Second Afﬁliated Hospital of Medical College, Xi’an
Jiaotong University, Xi’an 710004, China
Objectives: This study aims to evaluate the antioxidative
effects of caffeic acid phenethyl ester (CAPE) with various
doses, which was given by intraperitoneal injection or oral
route, in rats with chronic liver injury induced by carbon
tetrachloride (CCl4), alcohol and high-lipid forage.
Methods: Ninety-ﬁve Sprague-Dawley rats were divided
randomly into nine groups as follows: blank control, solvent
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controls, model group, the drug groups were administrated
with Vit E (10mg/kg, ip.) and CAPE (3mg/kg, 6mg/kg,
12mg/kg, ip. & 12mg/kg, 24mg/kg, ig.) daily throughout
10 weeks. At the end of the experiment, GSH, SOD and MDA
levels and CAT activity of liver homogenate were quantiﬁed.
Excised liver tissue was taken to undergo HE and Van Gieson
staining.
Results: Data showed decrease in MDA level and increase
in GSH, SOD levels, and CAT activity in the CAPE
treated groups, compared with model group. There were
statistically signiﬁcant difference between CAPE (12mg/kg,
6mg/kg, via ip route) groups and model group (p < 0.05),
and the other CAPE treated groups were not. What’s more,
treatment with CAPE attenuated the inﬂammation and
ﬁbroplasias induced by CCl4, alcohol and high-lipid forage.
In conclusion, CAPE protects against CCl4, alcohol and
high-lipid forage induced oxidative stress, and enhances
antioxidant capacity. In addition, intraperitoneal injection
is the better way to produce the best pharmacodynamic
effects.
PP-092 Clinical impacts of hypoxia inducible factor-1a
expression and its gene transcription in
HBV-related hepatocellular carcinoma
Z.Z. Dong1 *, D.F. Yao1, S.S. Li1, L.W. Qiu1. 1Research
Center of Clinical Medicine, Afﬁliated Hospital of Nantong
University, Nantong 226001, Jiangsu Province, China
Background: The progressing increasing of hypoxia inducible
factor-1alpha (HIF-1a) and HIF-1amRNA were found during
the malignant transformation of hepatocytes in our previous
work. In this study, the expression of hepatic HIF-1a
and level of its gene transcription were investigated in
different tissues of human hepatocellular carcinoma (HCC)
for exploring the relationship between HIF-1a expression
and HCC development.
Methods: The alterations of liver HIF-1a transcription
and expression were observed through the self-controlled
specimens from 35 human HCC patients. The expression
and cellular distribution of hepatic HIF-1a were analyzed
by immohistochemistry. The gene fragments of HIF-1amRNA
in different liver tissues were ampliﬁed by nested-PCR, and
conﬁrmed by sequencing.
Results: The positive HIF-1a was brown and granule-
like, mainly presented in cytoplasm and few in nucleus.
The incidence of HIF-1a expression was 80% (28/35) in
HCC, and 100% (35/35) in their paracancerous tissues,
respectively. The speciﬁc concentrations of total RNA were
12.4±7.3mg/mg wet liver in HCC and 53.8±52.0 mg/mg
wet liver in their paracancerous tissues (t = 3.05, P < 0.01).
The clinical pathological features of HIF-1a expression
demonstrated that no signiﬁcant correlation was found
between HIF-1a and tumor numbers, differentiation degree
or positive-HBsAg except of tumor size.
Conclusion: Hepatic HIF-1a expression is associated with
development and prognosis of HCC, and should be an
attractive molecular-target for HCC therapy.
PP-093 Hepatoma-speciﬁc glypican-3: expression in
hepatocarcinogenesis, pathological features and
clinical diagnostic value
M. Yao1, D.F. Yao1, J.L. Yang1, H.J. Zhang1. 1Research
Center of Clinical Medicine, Afﬁliated Hospital of Nantong
University, Nantong, 226001, China
Background: Hepatocellular carcinoma (HCC) prognosis is
poor and early diagnosis is of the utmost importance.
The objective of this study was to investigate the
dynamic expression of glypican-3 (GPC-3) and its gene in
hepatocarcinogenesis, the relationship of its expression with
HBV infection, and diagnostic values for HCC.
Methods: The characteristics of GPC-3 expression were
observed by rat hepatoma models. Liver GPC-3 Expression
was analyzed by immunohisto-chemistry or Western
blotting. Hepatic GPC-3 mRNAs were extracted and
ampliﬁed by using a nested polymerase chain reaction (PCR)
or real-time PCR assay. The ampliﬁed fragments of GPC-3
gene were conﬁrmed by DNA sequencing. The level of serum
GPC-3 in patients with liver diseases was quantitatively
detected by an ELISA method.
Results: The dynamic alteration of GPC-3 was conﬁrmed by
hepatoma models with brown granule-like staining localized
in membrane and cytoplasm in morphological stages of
granule-like degeneration, atypical hyperplasia and cancer
formation. Of self-control human HCC tissues, the incidence
of GPC-3 was 80.6% in HCC, 41.7% in their surrounding,
and none in distant group (c2 = 11.445, P < 0.000) with no
signiﬁcant relationship between GPC-3 and differentiation
grade or tumor number except of tumor size (Z = 2.941,
P = 0.003); and the features of circulating GPC-3 was
detected in only HCC patients (52.8%) without signiﬁcant
different between GPC-3 and sex, age, AFP, tumor number,
Child-pugh classiﬁcation or extrahepatic metastasis except
of size (c2 = 6.318, P = 0.012) and HBV infection (c2 = 23.362,
P < 0.000). Combined analysis of GPC-3 and AFP levels could
rise up to 87% for HCC diagnosis.
Conclusions: Abnormal expression of hepatic and circulating
GPC-3 may be associated closely with occurrence of HCC
and could be a useful speciﬁc molecular marker for HCC
diagnosis.
PP-094 The association of serum tissue inhibitor of
metalloproteinases-1 with hepatic ﬁbrosis in
patients with chronic hepatitis B
C.L. Zhu1, W.T. Li1, Y. Li1, Y. Tang1, Y.Y. Xu1, R.T. Gao1 *.
1Department of Infectious Disease, Anhui Provincial
Hospital, Anhui Medical University, China
Background: Chronic hepatitis B (CHB) is a severe
liver disease and can progressively develop hepatic
ﬁbrosis. Notably, high levels of tissue inhibitor of
metalloproteinases-1 (TIMP-1) expression are observed
in patients with liver ﬁbrosis. However, the potential
relationship between the levels of serum TIMP-1, hepatic
TIMP-1, and the degrees of hepatic ﬁbrosis in patients with
CHB has not yet been illustrated. This study aimed at
investigating the relationship between TIMP-1 expression
and liver ﬁbrosis severity in patients with CHB.
Methods: In the present study, a total of 159 CHB
with varying degrees of liver ﬁbrosis were recruited and
subjected to liver biopsy for the analysis of their liver
ﬁbrotic stages and inﬂammatory activities. The levels of
TIMP-1 expression in the liver tissues and serum TIMP-1 in
those patients were determined by immunohistochemistry
and enzyme-linked immunoabsorbent assay (ELISA),
respectively.
Results: Our results indicated that the concentrations of
serum TIMP were positively correlated with the levels
of TIMP-1 expression in the liver tissues (R = 0.9521) and
the degrees of liver ﬁbrosis (0.704) in CHB patients
with inﬂammation at grade 2. More importantly, the
concentrations of serum TIMP-1 were independent of the
degrees of inﬂammation in those patients.
Conclusion: Our ﬁndings suggest that the TIMP-1 may be a
valuable biomarker, and that the detection of serum TIMP-1
concentrations may be a safe and cost-effective measure
for the evaluation of liver ﬁbrosis at least in CHB patients.
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